Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.77 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.77 |
| ▸ | CCNA2 | P20248 | 15/20 | 0.77 |
| ▸ | CDK2 | P24941 | 15/20 | 0.77 |
| ▸ | CCNA1 | P78396 | 15/20 | 0.77 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.75 |
| ▸ | MGMT | P16455 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176198 | 1.00 | CDK1 (0.77) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| 6-Chloroguanine SCHEMBL17187927 | 0.91 | DPP4 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8971208 | 0.87 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL15643444 | 0.86 | CDK1 (0.76) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8074743 | 0.83 | CDK1 (1.00) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL231097 | 0.83 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| Methylguanine SCHEMBL29903462 | 0.83 | CDK1 (0.69) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL7807585 | 0.83 | CDK1 (0.76) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6925968 | 0.81 | CDK1 (0.74) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL8619367 | 0.81 | CDK1 (0.66) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-12226426-B2 | Combination therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-02-18 | — | — | US | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114901657-A | Antiviral and liver-targeting drugs | 人工智能生物制药公司 | 2022-08-12 | — | — | CN | claimed |
| US-20220031722-A1 | COMBINATION THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-02-03 | — | — | US | claimed |
| EP-3510170-B1 | CONVERTIBLE ADAPTERS | TECHNISCHE HOCHSCHULE WILDAU (DE) | 2021-10-13 | — | — | EP | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| EP-2909223-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | IDENIX Pharmaceuticals, Inc. (US) | 2015-08-26 | — | — | EP | claimed |
| WO-2014063019-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | WO | claimed |
| US-20140112886-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2014-04-24 | — | — | US | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140112886-A1 | DINUCLEOTIDE COMPOUNDS FOR HCV INFECTION | NSUN2, NUDT1, NSUN3 | CDK1 1047/4885CCNB1 868/4885CCNA2 783/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | CDK1 1061/4885CCNB1 600/4885CCNA2 634/4885 |
| US-12226426-B2 | Combination therapy | SAMHD1, POLRMT, AMPD3 | CDK1 4863/4885CCNB1 4601/4885CCNA2 3572/4885 |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | CDK1 573/4885CCNB1 1096/4885CCNA2 361/4885 |
| US-20220031722-A1 | COMBINATION THERAPY | SAMHD1, POLRMT, AMPD3 | CDK1 4863/4885CCNB1 4601/4885CCNA2 3572/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | CDK1 1403/4885CCNB1 1041/4885CCNA2 2596/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | CDK1 571/4885CCNB1 1131/4885CCNA2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.